Therapeutic Response

CCND1 status confers therapeutic sensitivity to Ibrutinib in patients with Mantle Cell Lymphoma.

Statements

Source and description

Ibrutinib Therapy - Mantle Cell Lymphoma. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved ibrutinib for reimbursement as a single agent treatment option for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. The treatment regimen further describes the eligibility criteria as requiring cyclin D1 overexpression or translocation breakpoints at t(11;14).